344 related articles for article (PubMed ID: 9513907)
41. Efficacy and Safety of Long-Term Corticosteroid Monotherapy in 26 Cases of Nephrotic Syndrome with Biopsy-Proven Membranous Nephropathy Induced by Seronegative Hepatitis B Virus-Associated Glomerulonephritis.
Zhang Y; Chen S; Yang D; Liu J; Zhang X; Yang X; Han H; Yang D
Nephron; 2021; 145(2):113-122. PubMed ID: 33561853
[TBL] [Abstract][Full Text] [Related]
42. Corticosteroids and ciclosporin A in idiopathic membranous nephropathy: higher remission rates of nephrotic syndrome and less adverse reactions than after traditional treatment with cytotoxic drugs.
Goumenos DS; Katopodis KP; Passadakis P; Vardaki E; Liakopoulos V; Dafnis E; Stefanidis I; Vargemezis V; Vlachojannis JG; Siamopoulos KC
Am J Nephrol; 2007; 27(3):226-31. PubMed ID: 17389782
[TBL] [Abstract][Full Text] [Related]
43. Treatment of childhood prednisone-resistant nephrotic syndrome and focal segmental glomerulosclerosis with intravenous methylprednisolone and oral alkylating agents.
Griswold WR; Tune BM; Reznik VM; Vazquez M; Prime DJ; Brock P; Mendoza SA
Nephron; 1987; 46(1):73-7. PubMed ID: 3600915
[TBL] [Abstract][Full Text] [Related]
44. Membranous nephropathy--still a treatment dilemma.
Cameron JS
N Engl J Med; 1992 Aug; 327(9):638-9. PubMed ID: 1640957
[No Abstract] [Full Text] [Related]
45. Tacrolimus combined with corticosteroids versus Modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: Randomized control trial.
Ramachandran R; Hn HK; Kumar V; Nada R; Yadav AK; Goyal A; Kumar V; Rathi M; Jha V; Gupta KL; Sakhuja V; Kohli HS
Nephrology (Carlton); 2016 Feb; 21(2):139-46. PubMed ID: 26205759
[TBL] [Abstract][Full Text] [Related]
46. Conservative versus immunosuppressive treatment of patients with idiopathic membranous nephropathy.
Torres A; Domínguez-Gil B; Carreño A; Hernández E; Morales E; Segura J; González E; Praga M
Kidney Int; 2002 Jan; 61(1):219-27. PubMed ID: 11786104
[TBL] [Abstract][Full Text] [Related]
47. A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy.
Jha V; Ganguli A; Saha TK; Kohli HS; Sud K; Gupta KL; Joshi K; Sakhuja V
J Am Soc Nephrol; 2007 Jun; 18(6):1899-904. PubMed ID: 17494881
[TBL] [Abstract][Full Text] [Related]
48. Treatment of progressive membranous glomerulopathy. A randomized trial comparing cyclophosphamide and corticosteroids with corticosteroids alone. The Glomerular Disease Collaborative Network.
Falk RJ; Hogan SL; Muller KE; Jennette JC
Ann Intern Med; 1992 Mar; 116(6):438-45. PubMed ID: 1371211
[TBL] [Abstract][Full Text] [Related]
49. ACTH and azathioprine: antiproteinuric and lipid-lowering effect in the course of idiopathic membranous glomerulonephritis.
Gigante A; Rosato E; Liberatori M; Gasperini ML; Giannakakis K; Barbano B; Cianci R; Salsano F; Amoroso A
J Biol Regul Homeost Agents; 2012; 26(1):135-8. PubMed ID: 22475105
[TBL] [Abstract][Full Text] [Related]
50. Prednisolone and chlorambucil therapy for idiopathic membranous nephropathy with progressive renal failure.
Warwick GL; Geddes CG; Boulton-Jones JM
Q J Med; 1994 Apr; 87(4):223-9. PubMed ID: 8208913
[TBL] [Abstract][Full Text] [Related]
51. Prednisolone and azathioprine in membranous nephropathy: a 10-year follow-up study.
Goumenos DS; Ahuja M; Davlouros P; El Nahas AM; Brown CB
Clin Nephrol; 2006 May; 65(5):317-23. PubMed ID: 16724651
[TBL] [Abstract][Full Text] [Related]
52. Controlled trial of monthly alternated courses of steroid and chlorambucil for idiopathic membranous nephropathy.
Ponticelli C; Zucchelli P; Imbasciati E; Cagnoli L; Pozzi C; Grassi C; Limido D; Pasquali S; Passerini P; Volpini T; Locatelli F
Proc Eur Dial Transplant Assoc; 1983; 19():717-23. PubMed ID: 6348763
[TBL] [Abstract][Full Text] [Related]
53. Short- and long-term efficacy of oral cyclophosphamide and steroids in patients with membranous nephropathy and renal insufficiency. Study Group.
Branten AJ; Wetzels JF
Clin Nephrol; 2001 Jul; 56(1):1-9. PubMed ID: 11499653
[TBL] [Abstract][Full Text] [Related]
54. Membranous nephropathy in children: clinical presentation and therapeutic approach.
Menon S; Valentini RP
Pediatr Nephrol; 2010 Aug; 25(8):1419-28. PubMed ID: 19908069
[TBL] [Abstract][Full Text] [Related]
55. Long-term outcome of patients with membranous nephropathy after complete remission of proteinuria.
Passerini P; Pasquali S; Cesana B; Zucchelli P; Ponticelli C
Nephrol Dial Transplant; 1989; 4(6):525-9. PubMed ID: 2507973
[TBL] [Abstract][Full Text] [Related]
56. Application of artificial neural networks in estimating predictive factors and therapeutic efficacy in idiopathic membranous nephropathy.
Naumovic R; Furuncic D; Jovanovic D; Stosovic M; Basta-Jovanovic G; Lezaic V
Biomed Pharmacother; 2010 Nov; 64(9):633-8. PubMed ID: 20888177
[TBL] [Abstract][Full Text] [Related]
57. Bortezomib therapy for nephrotic syndrome due to idiopathic membranous nephropathy.
Hartono C; Chung M; Kuo SF; Seshan SV; Muthukumar T
J Nephrol; 2014 Feb; 27(1):103-6. PubMed ID: 24430762
[TBL] [Abstract][Full Text] [Related]
58. Therapy for idiopathic membranous nephropathy: tailoring the choice by decision analysis.
Piccoli A; Pillon L; Passerini P; Ponticelli C
Kidney Int; 1994 Apr; 45(4):1193-202. PubMed ID: 8007591
[TBL] [Abstract][Full Text] [Related]
59. A review of therapeutic studies of idiopathic membranous glomerulopathy.
Hogan SL; Muller KE; Jennette JC; Falk RJ
Am J Kidney Dis; 1995 Jun; 25(6):862-75. PubMed ID: 7771482
[TBL] [Abstract][Full Text] [Related]
60. Comparative efficacy of 13 immunosuppressive agents for idiopathic membranous nephropathy in adults with nephrotic syndrome: a systematic review and network meta-analysis.
Zheng Q; Yang H; Liu W; Sun W; Zhao Q; Zhang X; Jin H; Sun L
BMJ Open; 2019 Sep; 9(9):e030919. PubMed ID: 31511292
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
